DPP4 and Hypoglycemia: These studies therefore show that DPP-4 inhibitors are safe from a cardiovascular point of view in subjects at risk for cardiovascular diseases and type 2 diabetes and, also, that risk for other adverse events, such as hypoglycemia or pancreatitis, is low.